

REMARKS

Claims 18-30, as amended, and new claims 39-58 are pending for the Examiner's consideration in this application. Applicants elect, with traverse, Group III, claims 18-30, directed to compositions of antibodies. Applicants traverse only with respect to modifying the restriction to request that Group I be examined with Group III. In particular, method claims 1-12 have been canceled and rewritten in substantially the same form as dependent claims 39-50, which now depend from the elected composition claims of Group III. As such, these dependent claims pose no additional searching burden. Claims 13-17 and 31-38 have also been canceled without prejudice to Applicant's rights to pursue such subject matter.

Various claims have been amended primarily to correct typographical or clerical errors. For example, independent claim 39 recites prophylactically or therapeutically (*See, e.g.*, Specification at page 23, ¶ 054-055). Several new claims have been added. Claim 51 recites preferred embodiments for instilling the composition. Claim 52 recites various indications wherein the patient is at risk of, or suffers from, at least one of cystic fibrosis, staphylococcal pneumonia, a staphylococcal contamination of a foreign body, a staphylococcal infection, and staphylococcal nasal colonization is *S. aureus*. Claims 53-54 recite preferred embodiments where the patient is a mammal or a human, respectively (*See, e.g.*, Specification at page 23, ¶ 054). Claim 55 recites that the staphylococcal infection includes *S. aureus* (*See, e.g.*, Specification at page 28, ¶ 062). Claims 56-58 recite various embodiments wherein an additional active pharmaceutical ingredient is also administered (*See, e.g.*, Specification at page 34-35, ¶ 078). No new matter has been introduced by these amendments or claim additions, such that the claims are in condition for entry and prosecution.

Applicant now believes all claims to be in condition for allowance. Should the Examiner not agree with this position, a telephone or personal interview is requested to resolve any remaining issues and expedite allowance of this application.

Respectfully submitted,

6/27/05
Date

Jeffrey A. Wolfson
Jeffrey A. Wolfson (Reg. No. 42,234)

WINSTON & STRAWN LLP
Customer No. 28765

202-282-5904